Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 7, 2019

View Archived Issues

Immunotherapeutic targeting of CD81 selectively kills B-cell lymphoma cells

Androgen receptor loss linked to increased transcription, translation

Parasite food fight

Recruitment ongoing in phase I study of DN-1406131

IKM-5 demonstrates promising safety and efficacy in breast cancer models

DKN-01 plus Keytruda shows positive clinical results in KEYNOTE-731 study

Interim data reported from ongoing phase Ib study of EDP-1815 in psoriasis

Syros Pharmaceuticals describes new CDK7/cyclin H inhibitors

Caspase-1 found to be protective in the pathogenesis of SLE

Indoleamine 2,3-dioxygenase 1 inhibitors discovered at Adlai Nortye

Enanta Pharmaceuticals discloses anti-hepatitis B virus compounds

New PI3K-delta inhibitors patented by Calitor Sciences, Sunshine Lake Pharma

Array BioPharma identifies new RET inhibitors

Oncternal opens enrollment in phase II portion of CIRLL study of cirmtuzumab plus ibrutinib

Topoisomerase inhibitors strongly downregulate MYC through binding the promoter G-quadruplex

Radius initiates phase III wearABLe study of abaloparatide-patch

Kineta receives further support to develop LHF-535 after positive phase I results

Noggin and asporin are diagnostic markers of NAFLD

FDA and Novartis comment on data accuracy issues with recently approved Zolgensma

DNARx to develop DNA-encoded gene-based therapeutics for pandemic influenza

Phase IIb study of OPT-302 in wet AMD meets primary endpoint

Promising new target identified for tissue regeneration

Topline results show BROADEN study of Waylivra met primary endpoint

Lynparza leads to improvement in men with mCRPC and HRR gene mutation

Positive preliminary data reported from phase I trial of INmune Bio's INB-03

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...